Jariani 2010.

Study characteristics
Methods	12‐week trial with 2 arms: olanzapine sertraline Duration of trial: 12 weeks Country: Iran Setting: outpatient
Participants	Methods of recruitment of patients: no information other than patients on methadone maintenance treatment with BPD diagnosis Overall sample size: 120 Diagnosis of borderline personality disorder: DSM‐IV‐TR Means of assessment: clinical interview Mean age: 27 years (SD = no information; range = no information) Sex: no information on percentage for overall sample size Comorbidity: 100% had a substance use disorder. Inclusion criteria: no information Exclusion criteria: no information; however, stated that patients did not suffer from any axis I disorders or other somatic disorders such as hepatitis or AIDS
Interventions	Experimental group Treatment name: olanzapine (5‐10 mg/d, exact mean final dose unclear) Number randomised to group: no information* Duration: 12 weeks Control/comparison group Comparison name: sertraline (50‐100 mg/d, exact mean final dose unclear) Number randomised to group: no information* Duration: 12 weeks Both groups Concomitant psychotherapy: no information Concomitant pharmacotherapy: methadone Proportions of participants taking standing medication during trial observation period: 100% of participants were concomitantly treated with methadone.
Outcomes	Primary outcomes Self‐harm (not further specified); not reported in trial, but reported a significant difference. Assessed at baseline, and at week 4, 8 and 12 (EOT) Mental health status (functioning), measured by SCL‐90‐R. Assessed at baseline, and at week 4, 8 and 12 (EOT) Secondary outcomes Anger, measured by SCL‐90‐R. Assessed at baseline, and at week 4, 8 and 12 (EOT) Interpersonal problems, measured by SCl‐90‐R. Assessed at baseline, and at week 4, 8 and 12 (EOT) Dissociation and psychotic‐like symptoms, measured by SCl‐90‐R. Assessed at baseline, and at week 4, 8 and 12 (EOT) Depression, measured by SCL‐90‐R. Assessed at baseline, and at week 4, 8 and 12 (EOT)
Notes	Sample calculation: yes Ethics approval: yes, "This clinical trial was granted an approval from Medical Ethics Committee at Lorestan Medical University on 12/04/2007". (Jariani 2010, p. 545) Funding source: unclear funding Conflicts of interest: No conflicts of interest were reported. Comments from trial authors (limitations): none mentioned Comments from review authors: *No information provided for the number of participants in each group and not possible to contact the authors
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: According to the sample size formula, 120 males and females on MMT with a diagnosis of BPD were chosen and randomly placed in two groups in which they received either olanzapine (5‐10 mg daily) or sertraline (50‐100 mg daily) (Jariani 2010, p. 545).
Allocation concealment (selection bias)	Unclear risk	Comment: no information on allocation concealment reported to permit a judgement of low or high risk of bias
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: no information on blinding reported to permit a judgement of low or high risk of bias
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: no information on blinding reported to permit a judgement of low or high risk of bias
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: The complete numbers of participants in each group were not provided for analysis results. No details given about patient flow after randomisation
Selective reporting (reporting bias)	Unclear risk	Comment: no protocol found
Vested Interest (funding and/or author affiliations)	Unclear risk	Comment: no information
Other bias	Low risk	Comment: no other sources found